Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 30, 2025 06:00 ET | Source: TOLREMO Therapeutics

TOLREMO therapeutics Welcomes Multiple Myeloma Leader Kenneth C. Anderson to its Scientific Advisory Board

TOLREMO therapeutics Welcomes Multiple Myeloma Leader Kenneth C. Anderson to its Scientific Advisory Board
August 28, 2025 05:00 ET | Source: TOLREMO Therapeutics

TOLREMO therapeutics Receives Two FDA Fast Track Designations for TT125-802 in Pretreated, Advanced or Metastatic NSCLC With Either an EGFR or a KRAS-G12C Mutation

TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung...
June 18, 2025 05:00 ET | Source: TOLREMO Therapeutics

TOLREMO therapeutics Announces Strengthening of Leadership: Alessandra Cesano Joins Board of Directors, Florian D. Vogl Appointed Chief Medical Officer

Basel, Switzerland – June 18, 2025 - TOLREMO therapeutics AG (TOLREMO), a clinical-stage biotechnology company developing TT125-802, a best-in-class CBP/p300 bromodomain inhibitor for the treatment of...
June 04, 2025 05:00 ET | Source: TOLREMO Therapeutics

TOLREMO therapeutics Announces TT125-802 is the First CBP/p300 Bromodomain Inhibitor to Show Clinical Activity in Solid Tumors

- Deep and durable responses in drug-resistant KRAS-G12C- and EGFR-mutant NSCLC - Best-in-class safety profile highlights potential for development in combination to treat patients with...
May 27, 2025 06:00 ET | Source: Athos KG

Strüngmann Award Committee Announces 2025 Finalists Recognizing Outstanding Life Science Entrepreneurs in the DACH Region

The selected finalists have demonstrated entrepreneurial execution and translational potential for a range of scientific approaches The winner(s) will be officially announced on July 3, 2025, and will...
May 27, 2025 06:00 ET | Source: Athos KG

Strüngmann Award ehrt herausragende Life-Science-Unternehmerinnen und Unternehmer aus der DACH-Region und gibt 2025 Finalisten bekannt

Die diesjährigen Finalistinnen und Finalisten überzeugten durch unternehmerische Exzellenz und großes Innovationspotenzial ihrer therapeutischen Ansätze über unterschiedliche wissenschaftliche...